Aripiprazole possibly worsens psychosis

Sriram Ramaswamy, Dewan Vijay, Marcil William, S. Pirzada Sattar, Fernandes Praveen, Frederick Petty

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Aripirazole is a novel antipsychotic that functions as a partial agonist at the dopamine D2 receptor and, thus, might theoretically worsen psychosis. We report a series of four clinical cases of exacerbation of psychosis related to initiation of aripiprazole therapy. Cases 1 and 2 demonstrated the worsening of psychosis following initiation of aripiprazole (15-30 mg daily) while tapering off the previous atypical antipsychotic. Cases 3 and 4 demonstrated worsening of psychosis following the addition of aripiprazole (15-30 mg daily) to an atypical antipsychotic. In two out of the four cases, discontinuation of arpiprazole resulted In improvement of psychotic symptoms. Although the cases presented are suggestive of a relationship between initiation of aripiprazole therapy and worsening of psychosis, further research is needed to clarify any potential association.

Original languageEnglish
Pages (from-to)45-48
Number of pages4
JournalInternational Clinical Psychopharmacology
Volume19
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Psychotic Disorders
Antipsychotic Agents
Dopamine D2 Receptors
Aripiprazole
Therapeutics
Research

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Aripiprazole possibly worsens psychosis. / Ramaswamy, Sriram; Vijay, Dewan; William, Marcil; Sattar, S. Pirzada; Praveen, Fernandes; Petty, Frederick.

In: International Clinical Psychopharmacology, Vol. 19, No. 1, 01.2004, p. 45-48.

Research output: Contribution to journalArticle

Ramaswamy, S, Vijay, D, William, M, Sattar, SP, Praveen, F & Petty, F 2004, 'Aripiprazole possibly worsens psychosis', International Clinical Psychopharmacology, vol. 19, no. 1, pp. 45-48. https://doi.org/10.1097/00004850-200401000-00009
Ramaswamy, Sriram ; Vijay, Dewan ; William, Marcil ; Sattar, S. Pirzada ; Praveen, Fernandes ; Petty, Frederick. / Aripiprazole possibly worsens psychosis. In: International Clinical Psychopharmacology. 2004 ; Vol. 19, No. 1. pp. 45-48.
@article{aef66ba5f9884513bd970456b3e8898f,
title = "Aripiprazole possibly worsens psychosis",
abstract = "Aripirazole is a novel antipsychotic that functions as a partial agonist at the dopamine D2 receptor and, thus, might theoretically worsen psychosis. We report a series of four clinical cases of exacerbation of psychosis related to initiation of aripiprazole therapy. Cases 1 and 2 demonstrated the worsening of psychosis following initiation of aripiprazole (15-30 mg daily) while tapering off the previous atypical antipsychotic. Cases 3 and 4 demonstrated worsening of psychosis following the addition of aripiprazole (15-30 mg daily) to an atypical antipsychotic. In two out of the four cases, discontinuation of arpiprazole resulted In improvement of psychotic symptoms. Although the cases presented are suggestive of a relationship between initiation of aripiprazole therapy and worsening of psychosis, further research is needed to clarify any potential association.",
author = "Sriram Ramaswamy and Dewan Vijay and Marcil William and Sattar, {S. Pirzada} and Fernandes Praveen and Frederick Petty",
year = "2004",
month = "1",
doi = "10.1097/00004850-200401000-00009",
language = "English",
volume = "19",
pages = "45--48",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Aripiprazole possibly worsens psychosis

AU - Ramaswamy, Sriram

AU - Vijay, Dewan

AU - William, Marcil

AU - Sattar, S. Pirzada

AU - Praveen, Fernandes

AU - Petty, Frederick

PY - 2004/1

Y1 - 2004/1

N2 - Aripirazole is a novel antipsychotic that functions as a partial agonist at the dopamine D2 receptor and, thus, might theoretically worsen psychosis. We report a series of four clinical cases of exacerbation of psychosis related to initiation of aripiprazole therapy. Cases 1 and 2 demonstrated the worsening of psychosis following initiation of aripiprazole (15-30 mg daily) while tapering off the previous atypical antipsychotic. Cases 3 and 4 demonstrated worsening of psychosis following the addition of aripiprazole (15-30 mg daily) to an atypical antipsychotic. In two out of the four cases, discontinuation of arpiprazole resulted In improvement of psychotic symptoms. Although the cases presented are suggestive of a relationship between initiation of aripiprazole therapy and worsening of psychosis, further research is needed to clarify any potential association.

AB - Aripirazole is a novel antipsychotic that functions as a partial agonist at the dopamine D2 receptor and, thus, might theoretically worsen psychosis. We report a series of four clinical cases of exacerbation of psychosis related to initiation of aripiprazole therapy. Cases 1 and 2 demonstrated the worsening of psychosis following initiation of aripiprazole (15-30 mg daily) while tapering off the previous atypical antipsychotic. Cases 3 and 4 demonstrated worsening of psychosis following the addition of aripiprazole (15-30 mg daily) to an atypical antipsychotic. In two out of the four cases, discontinuation of arpiprazole resulted In improvement of psychotic symptoms. Although the cases presented are suggestive of a relationship between initiation of aripiprazole therapy and worsening of psychosis, further research is needed to clarify any potential association.

UR - http://www.scopus.com/inward/record.url?scp=1642452858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642452858&partnerID=8YFLogxK

U2 - 10.1097/00004850-200401000-00009

DO - 10.1097/00004850-200401000-00009

M3 - Article

C2 - 15101571

AN - SCOPUS:1642452858

VL - 19

SP - 45

EP - 48

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 1

ER -